Human paraoxonase 1 (PON1) has been shown to decrease the level of systemic oxidative stress, which is thought to contribute to cancer devel- opment. The aim of this study was to examine the interrelationships between PON1 status and some clinical characteristics in patients with pancreatic cancer (PC). A group of 73 consecutive patients with PC (stage II-IV) and 73 control subjects were exam- ined. Laboratory studies included five polymor - phisms of the PON1 gene (L55M, Q192R, -108C/T, -126C/T, and -162A/G), PON1 arylesterase (PON1-A) and lactonase (PON1-L) activities, as well as some markers of protein metabolism, insulin resistance, and oxidative stress. In comparison with the control group, no difference in the distribution of the PON1 polymorphisms was found in cancer patients, both arylesterase and lactonase activities being signifi- cantly lower (-33, -47 %, respectively, both P < 0.001).
During the last twenty years, a cluster of risk factors called metabolic syndrome (MetS) attracts interest in preventive medicine. According to the prevailing notion, which evolved from clinical observations, the core of the MetS consists of visceral obesity, impaired metabolism of glucose, atherogenic dyslipidemia, and arterial hypertension. These risk factors tend to cluster and are believed to be causally associated with insulin resistance. Components of the MetS are to a various degree involved in chronic inflammation, prothrombotic state, endothelial dysfunction, and oxidative stress. Supporters of the concept of MetS as a physiological and clinical entity believe that systems approach can help in understanding pathogenesis, improve prediction of cardiovascular risk, and increase motivation for prevention and treatment. On the other hand, serious criticisms emerged, which concern insufficient experimental evidence, imprecise diagnostic criteria, and questionable justification in general practice. To clarify unresolved problems which evolved in the ongoing debate, further research is needed.